Filtered By:
Condition: Ischemic Stroke
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 963 results found since Jan 2013.
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial
CONCLUSIONS: Patients free from events at the end of the first year post-PCI and who adhered to their prescribed regimen had a reduced risk of ischaemic events compared to aspirin monotherapy in the second year post-PCI.CLINICALTRIALS: gov: NCT01813435.PMID:35260381 | DOI:10.4244/EIJ-D-21-00870
Source: EuroIntervention - March 9, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Masafumi Ono Hironori Hara Hideyuki Kawashima Chao Gao Rutao Wang Joanna J Wykrzykowska Jan J Piek Scot Garg Christian Hamm Philippe Gabriel Steg Marco Valgimigli Stephan Windecker Pascal Vranckx Yoshinobu Onuma Patrick W Serruys Source Type: research
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research
The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
CONCLUSIONS: Patients on combined oral anticoagulation and antiplatelet therapy undergoing PCI are elderly and have both a high bleeding and ischaemic risk. Over time, a NOAC plus clopidogrel became the preferred treatment. The rate of thrombotic and bleeding events was not significantly different between patients on triple or dual therapy or between those on VKAs versus NOACs.PMID:35230636 | DOI:10.1007/s12471-022-01664-0
Source: Netherlands Heart Journal - March 1, 2022 Category: Cardiology Authors: A J W M de Veer N Bennaghmouch W L Bor J P R Herrman M Vrolix M Meuwissen T Vandendriessche T Adriaenssens B de Bruyne M Magro W J M Dewilde J M Ten Berg Source Type: research
A comparison of drug ‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
ConclusionsConsidering the higher long-term survival rate and lower repeat-revascularization rate, CABG may be superior to DES implantation in patients with mildly to moderately reduced EF (35 –50%) and significant CAD.
Source: ESC Heart Failure - February 23, 2022 Category: Cardiology Authors: Kun Wang,
Le Wang,
Hongliang Cong,
Jingxia Zhang,
Yuecheng Hu,
Yingyi Zhang,
Rui Zhang,
Wenyu Li,
Wei Qi Tags: Original Article Source Type: research
Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.
Source: Cardiovascular Intervention and Therapeutics - February 9, 2022 Category: Cardiology Source Type: research
Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
CONCLUSIONS: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.PMID:35129316 | DOI:10.4070/kcj.2021.0293
Source: Korean Circulation Journal - February 7, 2022 Category: Cardiology Authors: You-Jeong Ki Bong Ki Lee Kyung Woo Park Jang-Whan Bae Doyeon Hwang Jeehoon Kang Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Dong-Bin Kim In-Ho Chae Keon-Woong Moon Hyun Woong Park Ki-Bum Won Dong Woon Jeon Kyoo-Rok Han Si Wan Choi Jae Kean Ryu Myu Source Type: research
